La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Viveve Medical Bilan de santé

Santé financière contrôle des critères 0/6

Données insuffisantes pour déterminer l'état de santé de Viveve Medical

Informations clés

n/a

Ratio d'endettement

n/a

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	n/a
Fonds propres	n/a
Total du passif	n/a
Total des actifs	n/a

Mises à jour récentes de la santé financière

Recent updates

Viveve to get US patent for technology to treat female stress urinary incontinence

Oct 04

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Dec 03

Analyse de la situation financière

Passif à court terme: Données insuffisantes pour déterminer si les actifs à court terme de VIVE couvrent ses passifs à court terme.

Passif à long terme: Données insuffisantes pour déterminer si les actifs à court terme de VIVE couvrent ses passifs à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: Données insuffisantes pour calculer le ratio dette nette/capitaux propres de VIVE afin de déterminer s'il est satisfaisant.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de VIVE a diminué au cours des 5 dernières années.

Couverture de la dette: Données insuffisantes pour déterminer si la dette de VIVE est bien couverte par le flux de trésorerie opérationnel.

Couverture des intérêts: Données insuffisantes pour déterminer si les paiements d'intérêts de VIVE sur sa dette sont bien couverts par l'EBIT.

Viveve Medical Bilan de santé

Santé financière contrôle des critères 0/6

Informations clés

Mises à jour récentes de la santé financière

Viveve Medical, Inc. Intends to File A Form 15 with the Securities and Exchange Commission

Viveve Medical Receives Notice from the Listing Qualifications Staff of Nasdaq

Viveve Medical Receives a Non-Compliance Letter from Nasdaq

Viveve Medical Receives a Letter from Nasdaq Regarding Minimum Bid Price Requirement

Viveve Regains Compliance with Nasdaq Continued Listing Rules

Recent updates

InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc.

Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index

Viveve Medical, Inc. Intends to File A Form 15 with the Securities and Exchange Commission

Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence

Viveve Medical Receives Notice from the Listing Qualifications Staff of Nasdaq

Viveve Medical Receives a Non-Compliance Letter from Nasdaq

Price target decreased to US$4.68

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viveve Medical, Inc. announced that it has received $0.014675 million in funding

Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve to get US patent for technology to treat female stress urinary incontinence

Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viveve Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Viveve Medical receives patent for dual-energy technology in Taiwan

Viveve Medical Receives a Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$6.88

Consensus revenue estimates fall by 15%

Price target decreased to US$9.63

Viveve Medical, Inc. Announces Initiation of Pivotal U.S. Pursuit Trial in Stress Urinary Incontinence

Viveve Medical, Inc. has completed a Composite Units Offering in the amount of $23.999988 million.

Viveve under pressure after upsizes capital raise, prices offering at $3.40

Viveve Regains Compliance with Nasdaq Continued Listing Rules

Viveve regains compliance with Nasdaq

Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Viveve Medical, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Viveve Medical, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Viveve Medical, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines